Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 7:16:17562872241229250.
doi: 10.1177/17562872241229250. eCollection 2024 Jan-Dec.

Oncological outcomes in robot-assisted radical prostatectomy: the value of PSA density as a preoperative predictive factor

Roser Vives Dilme  1 , Juan Gómez Rivas  2   3 , Laura Fernández Hernández  2 , Irene De la Parra Sánchez  2 , Rafael Sánchez Del Hoyo  4 , María Isabel Galante Romo  2 , Enrique Redondo González  2 , José Luis Senovilla Pérez  2 , Lorena Fernández Montarroso  2 , Jesús Moreno Sierra  2
Affiliations

Oncological outcomes in robot-assisted radical prostatectomy: the value of PSA density as a preoperative predictive factor

Roser Vives Dilme et al. Ther Adv Urol. .

Abstract

Background: Pretreatment assessment of patients diagnosed with localized prostate cancer (PCa) is essential for therapeutic decision-making. Currently available staging systems based on prostate-specific antigen (PSA), Gleason score, and clinical stage allow for determining the prognostic characteristics of these patients. Several studies have evaluated the preoperative use of prostate-specific antigen density (PSAD) as a prognostic factor for further risk stratification. To date, the role of PSAD in this setting is still an object of debate.

Objectives: The present analysis aimed to assess the predictive potential of PSAD for adverse oncological outcomes after robot-assisted radical prostatectomy (RARP) and to compare its accuracy to preoperative PSA (pPSA).

Design and methods: We retrospectively reviewed 427 patients diagnosed with localized PCa who underwent RARP at a single institution between January 2015 and January 2020. Generating receiver operator characteristic (ROC) curves, calculating areas under the curves (AUCs), and using a linear regression model, we analyzed the association of PSAD and pPSA with postoperative positive surgical margins (PSM), Gleason score ⩾ 7, persistent PSA, and biochemical recurrence (BCR), with a median follow-up of 47 months.

Results: PSAD showed a significant association with PSM (p < 0.0001), PSA persistence (p < 0.0001), and Gleason ⩾ 7 (p < 0.0001), without being statistically significant in predicting BCR (p = 0.098). The predictive value of PSAD was comparable to pPSA for outcomes of PSA persistence (AUC 0.727 versus 0.771) and Gleason ⩾ 7 (AUC 0.683 versus 0.649).

Conclusion: PSAD is a predictive factor for postoperative oncological outcomes of PSM, Gleason score ⩾ 7, and persistence of PSA. Despite the need for further studies, PSAD could be useful as a prognostic parameter in conjunction with established staging systems.

Keywords: oncological outcomes; prostate cancer; prostate-specific antigen; prostate-specific antigen density; robot-assisted radical prostatectomy.

Plain language summary

Oncological outcomes in robot-assisted radical prostatectomy: the value of PSA density as a preoperative predictive factor Prostate-specific antigen density (PSAD) has an established role in the diagnostic process of prostate cancer (PCa). However, controversy remains on the assessment of its value as a pretreatment prognostic factor. The aim of our study was to evaluate the predictive ability of PSAD for oncological outcomes in PCa patients treated with robot-assisted radical prostatectomy (RARP) and to compare with the value of preoperative PSA (pPSA). The present analysis showed a significant association of PSAD with positive surgical margins (PSM), Gleason Score >=7 and prostate-specific antigen (PSA) persistence after RARP. Moreover, PSAD demonstrated to perform comparably to pPSA in predicting the outcomes of clinically significant PCa (csPCa) and post-RARP PSA persistence. Therefore, PSAD is considered a preoperative predictive factor potentially useful in conjunction with other previously established prognostic criteria and clinical features.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
ROC curves and AUC show the performance of PSAD and pPSA in predicting postoperative outcomes. (a) Comparison of ROC curves and AUC of PSAD (blue line; AUC 0.727) and pPSA (red line; AUC 0.771) for prediction of PSA persistence and (b) comparison of ROC curves and AUC of PSAD (blue line; AUC 0.683) and pPSA (red line; AUC 0.649) for prediction of Gleason score ⩾ 7. AUC, area under the curve; pPSA, preoperative PSA; PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; ROC, receiver operator characteristic.
See this image and copyright information in PMC

References

    1. Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020; 77: 38. - PubMed
    1. International Agency for Research on Cancer (IARC); Data visualization tools for exploring the global cancer burden in 2020, https://gco.iarc.fr/roday/home (2020, accessed 22 January 2023).
    1. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. The 2022 update. Eur Urol 2022. - PubMed
    1. Knipper S, Graefen M. Robot-assisted radical prostatectomy – So successful because it is better or better because it is so successful? Eur Urol 2018; 1: 361–363. - PubMed
    1. Moreno Sierra J, Galante Romo MI, Senovilla Pérez JL, et al. Oncologic outcomes in 408 consecutive patient cohort treated with da Vinci robot-assisted radical prostatectomy. Actas Urol Esp 2020; 44: 179–186. - PubMed